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Giant cell tumor of bone (GCT-B) is a locally aggressive neo-
plasm composed of sheets of mononuclear cells admixed with 
uniformly distributed large osteoclast-like giant cells, primar-
ily affecting the metaphysis of long bones (Athanasou et al. 
2013). These cells express receptors of nuclear factor kappa-
B ligand (RANKL) (Atkins et al. 2000, Roux et al. 2002). 
GCT-B are rare; however, the incidence is not exactly known 
and is for example not stated in the World Health Organiza-
tion (WHO) classification of Tumors of Soft Tissue and Bone 
(Athanasou et al. 2013). The incidence was recently estimated 
at between 1.03 and 1.33 per million per year based on cancer 
registries in Australia, Japan and Sweden (Table 1) (Liede 
et al. 2014, Amelio et al. 2016). Median age of onset ranges 
between 20 and 40 years with an equal distribution between 
the sexes or a slight female predominance (Athanasou et al. 
2013, Amelio et al. 2016). 
Patients with GCT-B typically present with pain, swelling, 
and often decreased joint movement. In 5–30% of patients a 
pathologic fracture is noted (Athanasou et al. 2013, van der 
Heijden 2014b). Although this tumor rarely metastasizes, it 
is known to be locally aggressive, which may result in joint 
destruction and, uncommonly, neurological deficit in axial 
tumors (Athanasou et al 2013). Treatment options are curet-
tage, curettage with an adjuvant treatment, or resection with 
joint replacement (van der Heijden 2014a). In GCT-B the local 
recurrence rate is 6–42% (Balke et al. 2008, van der Heijden 
2014b). Recently, denosumab, a human IgG2 monoclonal 
antibody against RANKL, was registered for use in GCT-B 
and showed tumor response in 2 phase II studies (Thomas et 
al. 2010, Chawla et al. 2013).
According to our knowledge, current literature on GCT-B 
contains incidence calculations based solely on cancer registry 
studies. These studies are doctor-driven with a risk of under-
reporting (Table 1) (Liede et al. 2014, Amelio et al. 2016). In 
this study we use the non-profit nationwide network and reg-
Background and purpose — Giant cell tumors of bone 
(GCT-B) are rare, locally aggressive tumors characterized by 
an abundance of giant cells. Incidence studies for GCT-B are 
rare. This is the first study using a fully automated 100% 
covering pathology database, the nationwide Dutch Pathol-
ogy Registry (17 million inhabitants), PALGA, to calculate 
incidence rates for GCT-B.
Patients and methods — From PALGA, all pathology 
excerpts were retrieved for patients diagnosed with GCT-B, 
giant cell tumors of tenosynovium, and giant cell tumors of 
soft tissue between January 1, 2009 and December 31, 2013. 
The incidence of GCT-B was calculated.
Results — In total, 8,156 excerpts of 5,922 patients were 
retrieved; these included 138 first GCT-B diagnosis. For 
GCT-B the incidence was 1.7 per million inhabitants per 
year with a male to female ratio of 1:1.38 and a median age 
of 35 years (9–77). Most common localization was the femur 
(35%), followed by the tibia (18%). No differences in local-
ization according to age and sex were found. The incidence 
rate of local recurrence was 0.40 per million inhabitants per 
year.
Interpretation — This is the first nationwide study report-
ing the incidence of GCT-B, based on a nationwide pathol-
ogy database with 100% coverage of pathology departments. 
Current incidence calculations are based only on doctor-
driven registries. We confirmed that GCT-B is a rare disease 
with an incidence that is slightly higher than previously 
published. The relatively young median age of patients and 
the high incidence of recurrence stresses the importance of 
developing more effective treatments for this disease.
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istry of histo- and cytopathology in the Netherlands, PALGA. 
This fully automated nationwide database contains all pathol-
ogy reports in the Netherlands (17 million inhabitants) (Cas-
parie et al. 2007). In an effort not to miss GCT-B cases, our 
search included the following giant cell containing tumors: 
GCT-B, tenosynovial giant cell tumors, and giant cell tumors 
of soft tissue.
We calculated the incidence, demographics, and localiza-
tions of GCT-B in a nationwide pathology database study 
between January 1, 2009 and December 31, 2013.  
Patients and methods
Patients
PALGA covers all pathology reports of all pathology labo-
ratories in the Netherlands since 1993 (Casparie et al. 2007). 
Patient registration in PALGA is based on social service 
number and thereby multiple reports of one patient will be 
grouped and not lead to double registration of one patient. 
Excerpts matching our search criteria were retrieved from 
PALGA, encoded either as giant cell tumor of bone (PALGA 
code m9250*) or as giant cell tumor of tenosynovium 
(m9252*) or pigmented villonodular synovitis (m9252*) or 
giant cell tumor of soft tissue (m9251*) and terms separately 
used as free text between January 1, 2009 and December 31, 
2013 (Casparie et al. 2007). In our search, giant cell tumors 
of soft tissue and tenosynovium were included, to be as com-
prehensive as possible. Additionally, for all these patients his-
torical excerpts were retrieved matching our search criteria. 
When date of first diagnosis met our 5-year timeframe, the 
patient was included for incidence calculations. Patients with 
a giant cell tumor of the small bones of the hands or feet were 
excluded, since these are considered a separate entity accord-
ing to the current WHO classification of tumors of soft tissue 
and bone (Forsyth and Jundt 2013). Patients with a GCT-B 
affecting the mandible were also excluded, because these are 
probably central giant cell granulomas of the jaw (Jaffe 1953).
Based on the combination of the historical and current 
excerpts we could calculate the incidence of first local recur-
rences during the 5-year study period. It is essential to note 
that this is not the same as the incidence of recurrences for 
those patients diagnosed during these 5 years of study. To cal-
culate the latter, a longer interval between the study period and 
the moment of reporting would be necessary.
Excerpts contained an encrypted patient identification 
number (allowing for identification of multiple excerpts of 
one patient), data on age and sex, date of arrival of the histo-
logical tissue, and the conclusion of the pathology report. AJV 
extracted the data and uncertain pathology conclusions in the 
reports were discussed with HG and JVMGB. 
Disaggregated incidence rate calculations for localized 
and diffuse type are necessary in giant cell tumors of teno-
synovium. The PALGA database lacks information on tumor 
type (i.e., whether a giant cell tumor of tenosynovium is a 
localized type or a diffuse type as this is a combined diagno-
sis of radiological and pathological examinations), therefore 
additional chart review in giant cell tumors of tenosynovium 
was performed and published elsewhere (Mastboom et al. 
2017).
Data collection
Anonymized data were collected on age, sex, year of diagno-
sis, localization, GCT type, and date of local recurrence. 
Statistics
For statistical analysis, the Statistical Package for the Social 
Sciences (SPSS) version 23.0.0 (IBM Corp, Armonk, NY, 
USA) was used. Incidence of GCT-Bs was calculated per 
million inhabitants per year and standardized for 5-year age 
groups and sex for the Dutch population in 2012, as published 
by the Central Bureau of Statistics (CBS) (Statistics Neth-
erlands 2014). Incidence standardized to the WHO standard 
population for 5-year age groups was also calculated (Ahmad 
et al. 2001). 
We estimated first recurrences, defined as biopsied lesions 
or surgically treated recurrences, as the registry contained 
only reports for histological specimens. Both 95% confidence 
intervals (CI) for incidence rates (Mid-P exact) and frequen-
cies (Wilson score) were calculated using www.openepi.com.
Table 1. Review of all available incidence data on GCT-B 
   Incidence
   per million Age Percentage
Article Country Type inhabitants median (range) men
Liede et al. 2014 a Sweden, Australia,  Doctor-driven 1.03–1.33 20–40  (na) na
 Japan
Amelio et al. 2016 a Sweden Doctor-driven 1.3 34  (10–88) 48
Current study The Netherlands Nationwide 1.66 35  (9–77) 42
  pathology registry
na: not available. The study by Liede et al. does not report an exact median age, but only a median age group.
a These studies probably also included patients with a giant cell tumor of the small bones of hands or feet and 
patients with central giant cell granulomas of the jaw.
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Results
Search results
From PALGA, 8,156 excerpts of 5,922 patients were retrieved 
matching the search criteria (Figure 1). Of these 5,922 patients, 
5,756 patients were excluded. 151 new cases of GCT-B were 
identified; however, 13 of these new cases were actually not 
GCT-B, but either giant cell tumors of the small bones of 
hands or feet or central giant cell granulomas of the jaw. 15 
patients were only diagnosed with a first recurrence during the 
study period and had a primary tumor before the study period.
This resulted in 138 cases with a crude incidence rang-
ing from 1.3 to 2.1 per million inhabitants per year (mean: 
1.7; standard deviation (SD) 0.3; CI 1.4–2.0), age and sex 
corrected incidence ranged between 1.3 and 2.1 per million 
inhabitants per year (mean: 1.7; SD 0.3; CI 1.4–1.9), and the 
WHO standardized incidence was 1.4 to 2.3 per million inhab-
itants per year (mean: 1.7; SD 0.3; CI 1.4–2.0. Table 2 and 
Figure 2). 42% of patients were male (CI 34–50). The median 
age of patients was 35 years (9–77). 6% were below 18 years 
of age. The age distribution of GCT-B seems to be bimodal 
with a peak incidence between 20 and 39 and between 50 and 
59 years (Figure 3). Most affected localization was the femur 
(35%), followed by the tibia (18%) (Table 3). During these 
5 years, 33 patients were diagnosed with a first recurrence. 
Consequently, crude incidence of pathology confirmed first 
recurrence was 0.40 per million inhabitants per year (CI 0.28–
0.55). Median age of patients with a first recurrence was 32 
years (10–63). Median time between first diagnosis and first 
recurrence was 23 months (range 2–142). 30 % of the recur-
rences occurred within 1 year, 24% in the second year, and 30 
% in the third year after diagnosis. Most common localization 
of recurrence were the femur and tibia (both 30%; Table 4). 
Figure 1. Diagram showing inclusion and exclusion of all patients with GCT in the Neth-
erlands between 2009 and 2013.
Patients from PALGA
between 2009 and 2013
n = 5,922
Excluded patients (n = 5,756):
– diagnosis was not GCT, 848
– second opinion for foreign patients, 9
– uncertain diagnosis, 236
– GCT of tenosynovium, 4,663
Excluded because of 
localisation:
– hand and foot, 10
– mandibular, 3
Excluded because of 
localisation:
– hand and foot, 2
– mandibular, 1
Patients with a diagnosis
suggesting GCT-B
n = 166 
Patients with a diagnosis 
suggesting a first GCT-B
n = 151
Patients with a diagnosis suggesting
a first recurrence of GCT-B
n = 36
Patients with a diagnosis 
suggesting a first GCT-B
n = 138
Patients with a diagnosis suggesting
a first recurrence of GCT-B
n = 33 
Table 2. Overview of incidence rates
 Crude incidence per
 million inhabitants Age Percentage
 per year (CI) median (range) men (CI)
GCT-B total 1.7   (1.4–1.9) 35 (9–77) 42 (34–50)
Long bones 1.3   (1.1–1.6) 35 (9–77) 41 (33–51) 
Axial 0.35 (0.21–0.45) 38 (17–73) 46 (29–65)
Figure 2. Crude incidence rates of GCT-B in the 
Netherlands with 95% confidence interval.
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Figure 3. Age distribution of GCT-B in the Netherlands.
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Incidence rates for the long bones and the axial skeleton 
were 1.3 (CI 1.1–1.6) and 0.31 (CI 0.21–0.45) per million 
inhabitants per year, respectively (1 patient could not be allo-
cated to one of the groups). WHO standardized incidence rates 
were 1.40 and 0.31 per million per year. Incidence of recur-
rence were 0.32 (CI 0.21–0.47) and 0.07 (CI 0.03–0.15) per 
million per year. The median age of patients for the 2 groups 
was 35 (9–77) and 38 (17–73) years. Percentage of males was 
41% (CI 33–51) and 46% (CI 29–65) respectively. 
The localization of the tumors did not differ according to 
sex. Only 1 of the patients below 18 years of age had an axial 
localization of his GCT-B. However, this difference could be 
attributed to the low incidence of axial GCT-B.
During the 5-year study period, only 1 malignant GCT-B 
was reported.
 
Discussion
This is the first study on GCT-B incidence, based on a fully 
automated pathology database covering 100% of pathology 
reports in the Netherlands. Our calculated GCT-B incidence 
shows a higher number, compared with previously reported 
incidence rates (Table 1) (Liede et al. 2014, Amelio et al. 
2016). In addition, the study by Amelio et al. does not seem 
to exclude giant cell tumors of the small bones of the hands or 
feet and central giant cell granulomas of the jaw, suggesting 
that the actual incidence of giant cell tumors of bone in this 
study is actually lower (Amelio et al. 2016). However, this is 
not exactly stated in the paper, but derived from the graphs 
showing localizations. For the study by Liede et al. (2014), no 
data on localization were reported. The higher incidence may 
be explained by the use of the 100% covering Dutch nation-
wide pathology database PALGA. Incidence of GCT-B seems 
to decrease slightly during the 5 years of study; this could be 
attributed to a normal variation in the low absolute count of 
GCT-B per year. As expected, most GCT-Bs were localized in 
the lower, weight-bearing extremities, as described in previ-
ous studies (Liede et al. 2014, Amelio et al. 2016). Both slight 
female preponderance and age distribution are comparable to 
these earlier reports (Liede et al. 2014, Amelio et al. 2016). 
Age distribution seems to be bimodal (between 20 and 39 
years and 50 and 59 years of age), which is comparable to 
data described by Liede et al. (2014). However, this variation 
could also be due to the small number. 
GCT-Bs generally affect young patients (median age 35 
years) and 6% are younger than 18 years. This is lower com-
pared with the 14% in the Swedish study and the approxi-
mately 8% in Japan (manually calculated, based on published 
data) (Liede et al. 2014, Amelio et al. 2016). Reporting bias 
could be the cause of the higher percentage of patients < 18 
years with a GCT-B in the Swedish and Japanese registries, 
because these are doctor-driven registries. 
Although we do not calculate an exact incidence rate of first 
local recurrences for the patients diagnosed between 2009 and 
2013 in this study, we calculated an incidence of all first recur-
rences during this time period of 0.40 per million inhabitants 
per year. This results in a rate of recurrence of approximately 
24% (although the denominator is not exactly known), which 
is lower compared with the Swedish study (recurrence rate 
41%) (Liede et al. 2014, Amelio et al. 2016). 2 retrospective 
cohort studies reported rates of recurrence between 6 and 42% 
(Balke et al. 2008, van der Heijden 2014b). The relatively 
higher recurrence rate in the Swedish study could be attrib-
uted to an effect of reporting bias (patients with a recurrence 
will have a higher chance of being registered). The differences 
in recurrence could be caused by different treatment strate-
gies, which cannot be calculated in these studies due to a lack 
of data in our study and the other studies (van der Heijden 
2014b). 
Compared with the other studies, the reported incidence 
of malignant GCT-B (1 patient in 5 years, 1 of 138 patients) 
during these years was much lower than in the study by Liede 
et al. (27/337). We have no explanation for this difference.
In the future, additional nationwide studies are needed to 
calculate a more accurate worldwide incidence, because at the 
Table 3. Frequencies of localizations of first GCT-B
Localization Absolute frequency Percentage (CI)
Femur 48 35 (27–43)
Tibia 25 18 (12–25)
Radius 14 10 (6–16)
Fibula 13 9 (6–15)
Spine 13 9 (6–15)
Ulna 5 4 (2–8)
Pelvis 5 4 (2–8)
Humerus  2 1 (0–5) 
Mastoid 2 1 (0–5)
Patella 2 1 (0–5)
Scapula 2 1 (0–5)
Other * 3 2 (1–6)
Unknown 4 3 (1–7)
Total 138 100 
a
 Other: 4th rib, maxilla and petrous bone.
Table 4. Localization of recurrences
Localization Absolute frequency Percentage (CI)
Femur 10 30 (17–47)
Tibia 10 30 (17–47)
Spine 4 12 (5–27)
Radius 3 9 (3–24)
Humerus 2 6 (2–20)
Fibula 1 3 (1–15)
Ulna 1 3 (1–15)
Scapula 1 3 (1–15)
Pelvis 1 3 (1–15)
Total 33 100
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moment incidence rates only for countries in North and West 
Europe are available. Furthermore, the incidence calculations 
should include information on the incidence of GCT-B subdi-
vided into long bones and the axial skeleton. 
In summary, this study is the first to report incidence of 
GCT-B based on a 100% coverage nationwide pathology data-
base. These incidence numbers are of value for research and 
healthcare planning.
AJV, JVMGB, HG designed the study. AJV did the data collection and pri-
mary analysis of the data. All authors interpreted the data. AJV wrote the 
manuscript. All authors critically reviewed the manuscript and approved the 
final version.
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